INVEST IN THE Health Care Revolution.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): HUANG, NELLIE S. (AUTHOR)
  • Source:
    Kiplinger Personal Finance. Aug2020, Vol. 74 Issue 8, p14-18. 5p. 4 Color Photographs, 1 Chart.
  • Additional Information
    • Subject Terms:
      MEDICAL care; GOING public (Securities); MEDICAL technology equipment; MEDICAL technology
    • Abstract:
      The drug giant's 2019 acquisition of biotech firm Celgene added $18 billion in debt to its balance sheet, and some investors frowned on the deal. BofA Securities analyst Bob Hopkins expects Medtronic revenue to jump after 2021, with the launch of a new version of its leadless pacemaker, which will be suitable for a higher number of cardio patients, and the debut of the firm's long-anticipated robotic-assisted surgery system. Mid-stage tests of the firm's treatment for melanoma show that in 30% of cases, the therapy can shrink cancers, "head and shoulders above the 10% standard efficacy rate of other drugs", says Kumar. Iovance is a risky bet until the FDA approves the firm's TIL treatment. [Extracted from the article]
    • Abstract:
      Copyright of Kiplinger Personal Finance is the property of Future Publishing Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)